EYEPOINT PHARMACEUTICALS US, INC.

ACUITY PHARMACEUTICALS

House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma and diseases and conditions in joints, namely, osteoarthritis, bursitis, fibrotic diseases, and infections;House mark for sustained drug delivery systems for pharmaceuticals;PHARMACEUTICALS;

DELIVERING INNOVATION TO THE EYE

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease;Sustained drug delivery systems for ocular drugs;

DORATIQ

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma and diseases and conditions in joints, namely, osteoarthritis, bursitis, fibrotic diseases, and infections;Sustained drug delivery systems for pharmaceuticals;

DORTIQ

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma and diseases and conditions in joints, namely, osteoarthritis, bursitis, fibrotic diseases, and infections;Sustained drug delivery systems for pharmaceuticals;

DURAMAC

Pharmaceutical preparations for the treatment of eye diseases and conditions;

DURASERT

In the statement, line 4, through line 8, should be deleted, and injectable drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals via injection into the posterior chamber of the eye for the treatment of diseases and conditions, including ocular diseases, namely, uveitis and retinal disease should be inserted. In the statement, line 10 is deleted, and injectable sustained drug delivery systems for delivering pharmaceuticals via injection into the posterior chamber of the eye is inserted.;Injectable drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals via injection into the posterior chamber of the eye for the treatment of diseases and conditions, including ocular diseases, namely, uveitis and retinal disease;Injectable sustained drug delivery systems for delivering pharmaceuticals via injection into the posterior chamber of the eye;

DURAVU

Pharmaceutical preparations for the treatment of eye diseases and conditions;

DURAVUE

Pharmaceutical preparations for the treatment of eye diseases and conditions;

EYEPOINT

House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease;EYE POINT;House mark for sustained drug delivery systems for pharmaceuticals;

EYEPOINT

House mark for drug delivery agents consisting of polymer compounds that facilitate delivery of pharmaceutical preparations for the treatment of eye diseases and conditions; house mark for pharmaceutical preparations for ocular or intraocular surgery; house mark for pharmaceutical preparations for the treatment of ocular diseases and conditions;EYE POINT;

EYEPOINT ASSIST

EYE POINT ASSIST;Providing patient assistance programs, namely, administration of payment programs to assist eligible participants with payment of operation services in the nature of insurance claims administration and direct payment, charitable services, namely, providing patient financial assistance programs to provide copay assistance to eligible patients to reduce the cost of therapy; charitable services, namely, providing financial assistance programs to qualified uninsured and underinsured patients who have a demonstrated financial need for health services for purposes of enabling them to afford prescribed health services; program in the nature of providing financial information to healthcare providers and patients about healthcare insurance plans, medication insurance coverage, and insurance payer policies; healthcare insurance services, namely, benefit verification services, insurance authorization support and information, and claims and billing information and assistance; providing patient assistance programs, namely, insurance claims administration for individuals in the nature of assisting patients with preparation of insurance claims; charitable services, namely, providing patient financial assistance programs to provide free and low-cost prescriptions to low-income patients without prescription drug coverage; charitable services, namely, providing patient assistance programs, namely, financial administration of payment programs to assist eligible participants with payment of operation services by providing free and low-cost operation services to low-income patients without adequate medical coverage;Program in the nature of providing medical information to healthcare providers and patients about medication;ASSIST;

EYEPOINT PHARMACEUTICALS

House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease;EYE POINT PHARMACEUTICALS;House mark for sustained drug delivery systems for pharmaceuticals;PHARMACEUTICALS;

EYEPOINT PHARMACEUTICALS

House mark for drug delivery agents consisting of polymer compounds that facilitate delivery of pharmaceutical preparations for the treatment of eye diseases and conditions; house mark for pharmaceutical preparations for ocular or intraocular surgery; house mark for pharmaceutical preparations for the treatment of ocular diseases and conditions;PHARMACEUTICALS;

MAINTIK

Pharmaceutical preparations for the treatment of eye diseases and conditions;

MAINTIQ

Pharmaceutical preparations for the treatment of eye diseases and conditions;

MILLISERT

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma;Sustained drug delivery systems for ocular drugs;

OCUDUR

Pharmaceutical preparations for the treatment of eye diseases and conditions;

OCUNIB

Pharmaceutical preparations for the treatment of eye diseases and conditions;

OPVU

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RETINVU

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RETISTA

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RETIVU

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RETYSTA

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RYLYX

Pharmaceutical preparations for the treatment of eye diseases and conditions;

RYVIZ

Pharmaceutical preparations for the treatment of eye diseases and conditions;

TEVIDO

Pharmaceutical preparations for the treatment of eye diseases and conditions;

TREAT AND MAINTAIN

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion and retinal disease; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion and retinal disease;Sustained drug delivery systems for ocular drugs;

UVIEY

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, age-related macualr degeneration, retinal disease, and glaucoma;The non-Latin characters in the mark transliterate to UVIEY and this has no meaning in a foreign language.;The wording UVIEY has no meaning in a foreign language.;Sustained drug delivery systems for ocular drugs;

UVISERT

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma;Sustained drug delivery systems for ocular drugs;

VISITAIN

Pharmaceutical preparations for the treatment of eye diseases and conditions;

VIZIQ

Pharmaceutical preparations for the treatment of eye diseases and conditions;

VODURA

Pharmaceutical preparations for the treatment of eye diseases and conditions;

VORVIZIX

Pharmaceutical preparations for the treatment of eye diseases and conditions;

VUDUR

Pharmaceutical preparations for the treatment of eye diseases and conditions;

WITH AN EYE ON PATIENTS

Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease;Sustained drug delivery systems for ocular drugs;

YUTIQ

In the statement, lines 4-9, is deleted, and CLASS 5: Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease is inserted.;Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and [ retinal vein occlusion, macular edema, macular disease, ] retinal disease; [ and glaucoma; ] pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis and [ retinal vein occlusion, macular edema, macular disease, age-related macular degeneration, ] retinal disease [ and glaucoma ];The non-Latin characters in the mark transliterate to YUTIQ and this has no meaning in a foreign language.;The wording YUTIQ has no meaning in a foreign language.;Sustained drug delivery systems for ocular drugs;

YUTIQ

The mark consists of the word YUTIQ and three curved bands that converge together to the left of the word YUTIQ.;Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease;Color is not claimed as a feature of the mark.;The wording YUTIQ has no meaning in a foreign language.;Sustained drug delivery systems for ocular drugs;